{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:01:55Z","timestamp":1775520115800,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T00:00:00Z","timestamp":1649116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T00:00:00Z","timestamp":1649116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Insulin-like growth factor (IGF)-1 participates in modulating immunity and inflammation. Its bioactivity is controlled by six IGF-binding proteins (IGFBP-1 to IGFBP-6). In particular, the IGFBP-3 level is reportedly linked to the disease activity of rheumatoid arthritis (RA), consistent with our previous study. Therefore, the present study aimed to reproduce the previous results.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The serum IGFBP-3 level was not significantly different among the three groups according to disease activity based on the DAS28-ESR\/CRP (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05) but was significantly different between the low- and high-disease-activity groups based on the DAS28-CRP (<jats:italic>p<\/jats:italic>\u2009=\u20090.036). Meanwhile, the interleukin-6 (IL-6) level moderately correlated with DAS28-CRP (Spearman\u2019s rho\u2009=\u20090.583,<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13104-022-06008-0","type":"journal-article","created":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T11:09:36Z","timestamp":1649156976000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Serum IGF-1 in patients with rheumatoid arthritis: correlation with disease activity"],"prefix":"10.1186","volume":"15","author":[{"given":"Hanna","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Sun","family":"Suh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Il","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-Hong","family":"Cheon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingyo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hae Sook","family":"Noh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0904-1584","authenticated-orcid":false,"given":"Hyun-Ok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,5]]},"reference":[{"key":"6008_CR1","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/cei.12374","volume":"177","author":"MC Lu","year":"2014","unstructured":"Lu MC, Yu CL, Chen HC, Yu HC, Huang HB, Lai NS. Increased miR-223 expression in T cells from patients with rheumatoid arthritis leads to decreased insulin-like growth factor-1-mediated interleukin-10 production. Clin Exp Immunol. 2014;177:641\u201351.","journal-title":"Clin Exp Immunol"},{"key":"6008_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S1359-6101(98)00022-7","volume":"10","author":"VH Heemskerk","year":"1999","unstructured":"Heemskerk VH, Daemen MA, Buurman WA. Insulin-like growth factor-1 (IGF-1) and growth hormone (GH) in immunity and inflammation. Cytokine Growth Factor Rev. 1999;10:5\u201314.","journal-title":"Cytokine Growth Factor Rev"},{"key":"6008_CR3","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1093\/rheumatology\/41.3.352","volume":"41","author":"T Matsumoto","year":"2002","unstructured":"Matsumoto T, Tsurumoto T. Inappropriate serum levels of IGF-1 and IGFBP-3 in patients with rheumatoid arthritis. Rheumatology (Oxford). 2002;41:352\u20133.","journal-title":"Rheumatology (Oxford)"},{"key":"6008_CR4","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1161\/01.ATV.0000105902.89459.09","volume":"24","author":"P Delafontaine","year":"2004","unstructured":"Delafontaine P, Song YH, Li Y. Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arterioscler Thromb Vasc Biol. 2004;24:435\u201344.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"6008_CR5","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1210\/er.2008-0028","volume":"30","author":"S Jogie-Brahim","year":"2009","unstructured":"Jogie-Brahim S, Feldman D, Oh Y. Unraveling insulin-like growth factor binding protein-3 actions in human disease. Endocr Rev. 2009;30:417\u201337.","journal-title":"Endocr Rev"},{"key":"6008_CR6","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S1063-4584(05)80102-5","volume":"4","author":"CW Denko","year":"1996","unstructured":"Denko CW, Boja B, Moskowitz RW. Growth factors, insulin-like growth factor-1 and growth hormone, in synovial fluid and serum of patients with rheumatic disorders. Osteoarthritis Cartilage. 1996;4:245\u20139.","journal-title":"Osteoarthritis Cartilage"},{"key":"6008_CR7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.semarthrit.2005.03.001","volume":"35","author":"CW Denko","year":"2005","unstructured":"Denko CW, Malemud CJ. Role of the growth hormone\/insulin-like growth factor-1 paracrine axis in rheumatic diseases. Semin Arthritis Rheum. 2005;35:24\u201334.","journal-title":"Semin Arthritis Rheum"},{"key":"6008_CR8","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/art.38303","volume":"66","author":"HS Lee","year":"2014","unstructured":"Lee HS, Woo SJ, Koh HW, et al. Regulation of apoptosis and inflammatory responses by insulin-like growth factor binding protein 3 in fibroblast-like synoviocytes and experimental animal models of rheumatoid arthritis. Arthritis Rheumatol. 2014;66:863\u201373.","journal-title":"Arthritis Rheumatol"},{"key":"6008_CR9","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1002\/art.1780390916","volume":"39","author":"JK Fernihough","year":"1996","unstructured":"Fernihough JK, Billingham ME, Cwyfan-Hughes S, Holly JM. Local disruption of the insulin-like growth factor system in the arthritic joint. Arthritis Rheum. 1996;39:1556\u201365.","journal-title":"Arthritis Rheum"},{"key":"6008_CR10","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1093\/rheumatology\/41.3.352","volume":"41","author":"T Matsumoto","year":"2002","unstructured":"Matsumoto T, Tsurumoto T. Inappropriate serum levels of IGF-I and IGFBP-3 in patients with rheumatoid arthritis. Rheumatology (Oxford). 2002;41:352\u20133.","journal-title":"Rheumatology (Oxford)"},{"key":"6008_CR11","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1002\/art.30527","volume":"63","author":"EA Bostrom","year":"2011","unstructured":"Bostrom EA, Svensson M, Andersson S, Jonsson IM, Ekwall AK, Eisler T, et al. Resistin and insulin\/insulin-like growth factor signaling in rheumatoid arthritis. Arthritis Rheum. 2011;63:2894\u2013904.","journal-title":"Arthritis Rheum"},{"key":"6008_CR12","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1002\/1529-0131(200109)44:9<2009::AID-ART349>3.0.CO;2-L","volume":"44","author":"PM Welsing","year":"2001","unstructured":"Welsing PM, van Gestel AM, Swinkels HL, Kiemeney LA, van Riel PL. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum. 2001;44:2009\u201317.","journal-title":"Arthritis Rheum"},{"key":"6008_CR13","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1203\/00006450-199912000-00019","volume":"46","author":"W Tu","year":"1999","unstructured":"Tu W, Cheung PT, Lau YL. IGF-1 increases interferon-gamma and IL-6 mRNA expression and protein production in neonatal mononuclear cells. Pediatr Res. 1999;46:748\u201354.","journal-title":"Pediatr Res"},{"key":"6008_CR14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1124\/pr.109.002469","volume":"62","author":"JS Terry","year":"2010","unstructured":"Terry JS. Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune disease? Pharmacol Rev. 2010;62:199\u2013236.","journal-title":"Pharmacol Rev"},{"key":"6008_CR15","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1172\/JCI113703","volume":"82","author":"VF Tapson","year":"1988","unstructured":"Tapson VF, Boni-Schnetzler M, Pilch PF, Center DM, Berman JS. Structural and functional characterization of the human T lymphocyte receptor for insulin-like growth factor-I in vitro. J Clin Invest. 1988;82:950\u20137.","journal-title":"J Clin Invest"},{"key":"6008_CR16","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1046\/j.1365-2567.2002.01525.x","volume":"107","author":"PT Walsh","year":"2002","unstructured":"Walsh PT, Smith LM, O\u2019Connor R. Insulin-like growth factor-1 activates Akt and Jun N-terminal kinases (JNKs) in promoting the survival of T lymphocytes. Immunology. 2002;107:461\u201371.","journal-title":"Immunology"},{"key":"6008_CR17","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.4049\/jimmunol.165.3.1331","volume":"165","author":"W Tu","year":"2000","unstructured":"Tu W, Cheung PT, Lau YL. Insulin-like growth factor 1 promotes cord blood T cell maturation and inhibits its spontaneous and phytohemagglutinin-induced apoptosis through different mechanisms. J Immunol. 2000;165:1331\u20136.","journal-title":"J Immunol"},{"key":"6008_CR18","doi-asserted-by":"crossref","first-page":"5791","DOI":"10.4049\/jimmunol.158.12.5791","volume":"158","author":"TK Teague","year":"1997","unstructured":"Teague TK, Marrack P, Kappler JW, Vella AT. IL-6 rescues resting mouse T cells from apoptosis. J Immunol. 1997;158:5791\u20136.","journal-title":"J Immunol"},{"key":"6008_CR19","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1177\/1759720X10378372","volume":"2","author":"S Srirangan","year":"2010","unstructured":"Srirangan S, Choy EH. The role of interleukin 6 in the pathophysiology of rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2010;2:247\u201356.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"6008_CR20","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3389\/fmed.2018.00040","volume":"5","author":"H Canh\u00e3o","year":"2018","unstructured":"Canh\u00e3o H, Rodrigues AM, Greg\u00f3rio MJ, Dias SS, Melo Gomes JA, Santos MJ, et al. Common evaluations of disease activity in rheumatoid arthritis reach discordant classification across different populations. Front Med (Lausanne). 2018;5:40.","journal-title":"Front Med (Lausanne)"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-022-06008-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13104-022-06008-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-022-06008-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T16:52:12Z","timestamp":1675183932000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/s13104-022-06008-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,5]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["6008"],"URL":"https:\/\/doi.org\/10.1186\/s13104-022-06008-0","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,5]]},"assertion":[{"value":"9 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approved by Gyeongsang National Changwon Hospital Institutional Review Board with the written informed consent from participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"128"}}